araag2/HINT huggingface dataset:
Clinical trial NCT02128763 (phase 3, status: completed)
Conditions: dry eye
ICD codes: H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, H35.3121
Drugs: omega-3 supplements, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Greater than or equal to 2 of the following 4 signs in the same eye at screening and
             baseline visits (Same signs must be present at Screening and Baseline visits):
             Conjunctival staining present greater than or equal to 1 (out of possible score of 6
             per eye), Corneal fluorescein staining present greater than or equal to 4 (out of a
             possible score of 15 per eye), Tear film break up time (TBUT) less than or equal to 7
             seconds, Schirmer's test greater than or equal to 1 to less than or equal to 7 mm in 5
             minutes.

          -  Ocular Surface Disease Index (OSDI) score: 25-80 at screening, 21-80 at baseline.

          -  Symptoms of DED for greater than or equal to 6 months.

          -  Use of or desire to use artificial tears at least 2 times per day in preceding 2
             weeks.

          -  Ability to swallow large, soft gelcaps

        Exclusion Criteria:

          -  Allergic to ingredients in supplements or placebo

          -  Contact lens wear

          -  Pregnant, nursing, or lactating

          -  Current ocular infection, inflammation, or acute allergic conjunctivitis

          -  History of: ocular herpetic keratitis, ocular surgery in past 6 months, LASIK surgery,
             use of glaucoma medicine or surgery for glaucoma, liver disease, atrial fibrillation,
             hemophilia or bleeding tendencies

          -  Currently on anticoagulation therapy

          -  Eyelid abnormalities or extensive ocular scarring

          -  Use of EPA/DHA supplements in excess of 1200 mg per dayi

          -  Current use, insufficient washout period, or intent to change specific treatments for
             dry eye disease
Clinical trial NCT02130557 (phase 3, status: completed)
Conditions: leukemia, myelogenous, chronic, breakpoint cluster region-abelson proto-oncogene (bcr-abl) positive
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: bosutinib, imatinib
SMILES: COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Eligibility criteria:

        Inclusion Criteria:

          1. Molecular diagnosis of CP CML of ≤ 6 months (from initial diagnosis).

          2. Adequate hepatic, renal and pancreatic function.

          3. Age ≥ 18 years.

        Exclusion Criteria:

          1. Any prior medical treatment for CML, including tyrosine kinase inhibitors (TKIs), with
             the exception of hydroxyurea and/or anagrelide treatment, which are permitted for up
             to 6 months prior to study entry (signature of ICF) if suitably approved for use in
             the subject's region.

          2. Any past or current Central Nervous System (CNS) involvement, including leptomeningeal
             leukemia.

          3. Extramedullary disease only.

          4. Major surgery or radiotherapy within 14 days of randomization.

          5. History of clinically significant or uncontrolled cardiac disease.

          6. Known seropositivity to human immunodeficiency virus (HIV), current acute or chronic
             hepatitis B (hepatitis B surface-antigen positive), hepatitis C, cirrhosis or evidence
             of decompensated liver disease. Patients with resolved Hepatitis B can be included.

          7. Recent or ongoing clinically significant GI disorder, e.g. Crohn's Disease, Ulcerative
             Colitis, or prior total or partial gastrectomy.

          8. History of another malignancy within 5 years with the exception of basal cell
             carcinoma or cervical carcinoma in situ or stage 1 or 2 cancer that is considered
             adequately treated and currently in complete remission for at least l2 months.

          9. Current, or recent (within 30 days, or 5 half-lives of investigational product)
             participation in other clinical trials of investigational agents and/or containing
             interventional procedures deemed contrary to the objectives and conduct of this trial.
Clinical trial NCT02131233 (phase 3, status: completed)
Conditions: hiv infection
ICD codes: Z21
Drugs: reformulated raltegravir, raltegravir, truvada™, placebo to reformulated raltegravir, placebo to raltegravir
SMILES: CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1, CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  HIV-1 positive

          -  Naïve to antiretroviral therapy including investigational antiretroviral agents

          -  Not of reproductive potential or, if of reproductive potential agrees to 1) true
             abstinence, or 2) use of an acceptable method of birth control during the study

        Exclusion Criteria:

          -  Use of recreational or illicit drugs or has recent history of drug or alcohol abuse or
             dependence

          -  Has been treated for a viral infection other than HIV-1 (such as hepatitis B) with an
             agent that is active against HIV-1 including but not limited to adefovir, tenofovir,
             entecavir, emtricitabine, or lamivudine

          -  Has documented or known resistance to raltegravir, emtricitabine, and/or tenofovir
             before the first dose of study drug

          -  Has participated in a study with an investigational compound or device within 30 days
             or anticipates participating in such a study during this study

          -  Has used systemic immunosuppressive therapy or immune modulators within 30 days or is
             anticipated to need them during the study (short courses of corticosteroids are
             allowed)

          -  Requires or is anticipated to require any of the following prohibited medications
             while in the study: phenobarbital, phenytoin, rifampin, rifabutin, or calcium,
             magnesium and aluminum containing antacids, such as TUMS™, Maalox™ and Milk of
             Magnesia™

          -  Has significant hypersensitivity or other contraindication to any of the components of
             the study drugs

          -  Has current, active diagnosis of acute hepatitis due to any cause

          -  Is pregnant, breastfeeding, or expecting to conceive during the study

          -  Female participant expecting to donate eggs or male participant expecting to donate
             sperm during the study

          -  Is or has a family member (spouse or children) who is investigational staff or sponsor
             staff directly involved in this trial
Clinical trial NCT02131272 (phase 3, status: terminated)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin detemir, insulin nph
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent from the subject or a legally acceptable representative (LAR) and
             child assent from the subject obtained before any trial-related
             activities.Trial-related activities are any procedures that are carried out as part of
             the trial, including activities to determine suitability for the trial

          -  Male or female, above or equal to 10 years and below or equal to 17 years at the time
             of signing informed consent/assent

          -  Diagnosis of type 2 diabetes mellitus at least 3 months prior to screening

          -  Treated with the maximum tolerated stable dose of metformin for at least 3 months
             prior to screening or have documented complete metformin intolerance

          -  HbA1c (glycosylated haemoglobin) above or equal to 7.0% and below or equal to 10.5%
             (above or equal to 53 mmol/mol and below or equal to 91 mmol/mol) at screening

        Exclusion Criteria:

          -  Maturity onset diabetes of the young (MODY)

          -  Fasting C-peptide at screening below 0.6 ng/mL

          -  Impaired liver function defined as alanine aminotransferase (ALT) above or equal to
             2.5 times upper normal limit

          -  Known proliferative retinopathy or maculopathy requiring acute treatment as judged by
             the investigator

          -  Treatment with any medication for the indication of diabetes or obesity other than
             stated in the inclusion criteria in a period of 3 months before the day of screening
Clinical trial NCT02132936 (phase 3, status: completed)
Conditions: psoriasis vulgaris
ICD codes: L40.0
Drugs: leo 90100 aerosol foam, aerosol foam vehicle, calcipotriol bdp gel, gel vehicle
SMILES: CC1=CC(O)=CC(C)=C1Cl, O[C@H](\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)C1CC1, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18 years or above

          -  Psoriasis vulgaris on the trunk and/or limbs (excluding psoriasis on the genitals and
             skin folds) involving 2-30% of the Body Surface Area (BSA)

          -  A Physician's Global Assessment of disease severity (PGA) of at least mild on trunk
             and limbs

          -  A modified Psoriasis Area Severity Index (PASI) score of at least 2 on the trunk and
             limbs.

        Exclusion Criteria:

          -  Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis

          -  Systemic treatment with biological therapies, whether marketed or not, with a possible
             effect on psoriasis vulgaris within the following time periods prior to randomisation:

               -  etanercept - within 4 weeks prior to randomisation

               -  adalimumab, infliximab - within 8 weeks prior to randomisation

               -  ustekinumab - within 16 weeks prior to randomisation

               -  other products - within 4 weeks/5 half-lives prior to randomisation (whichever is
                  longer)

          -  Systemic treatment with all other therapies with a possible effect on psoriasis
             vulgaris (e.g. corticosteroids, retinoids, methotrexate, ciclosporin and other
             immunosuppressants within 4 weeks prior to randomisation)

          -  Subjects who have received treatment with any non-marketed drug substance (i.e. a drug
             which has not yet been made available for clinical use following registration) within
             4 weeks/5 half-lives (whichever is longer) prior to randomisation.

          -  Psoralen combined with Ultraviolet A (PUVA) therapy within 4 weeks prior to
             randomisation

          -  Ultraviolet B (UVB) therapy within 2 weeks prior to randomisation

          -  Topical anti-psoriatic treatment on the trunk and limbs (except for emollients) within
             2 weeks prior to randomisation

          -  Topical treatment on the face, scalp and skin folds with corticosteroids, vitamin D
             analogues or prescription shampoos within 2 weeks prior to randomisation

          -  Females who are pregnant, wishing to become pregnant during the trial or are
             breastfeeding
Clinical trial NCT02133105 (phase 3, status: completed)
Conditions: cardiorenal syndrome
ICD codes: Q93.81, B33.4, A36.81, A50.54, A52.00, A52.09, B33.24
Drugs: levosimendan, dobutamine
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, NC[C@H](O)C1=CC(O)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Written, signed and dated informed consent

          -  Male and Female subjects ≥18 years of age

          -  Chronic congestive heart failure scheduled for right sided cardiac catheterization

          -  Left ventricular ejection fraction ≤ 40% determined by echocardiography

          -  Elevation of N Terminal-proBNP ≥ 500 ng/L

          -  Cardiorenal syndrome (30ml/min ≤ estimated GFR ≤ 80 ml/min (MDRD)

        Exclusion Criteria:

          -  Acute heart failure, untreated

          -  Systolic blood pressure < 80 mmHg

          -  Tachycardia above 100 bpm

          -  Angina Canadian Cardiovascular Society (CCS) class III or higher

          -  Aortic stenosis

          -  Hypertrophic cardiomyopathy

          -  Restrictive cardiomyopathy

          -  The presence of kidney disease diagnosed before heart failure

          -  Administration of radiographic contrast < 1 week

          -  Radiographic contrast allergy

          -  In the Investigator's opinion, the patient has a clinically significant disease that
             could be adversely affected by study participation
Clinical trial NCT02133989 (phase 3, status: unknown status)
Conditions: carotid stenosis
ICD codes: I65.21, I65.22, I65.23, I65.29, I63.231, I63.232, I63.233
Drugs: ticlopidine + ginko biloba, clopidogrel
SMILES: ClC1=CC=CC=C1CN1CCC2=C(C1)C=CS2, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients scheduled for stent implantation due to carotid stenosis

          -  Patients resistant to clopidogrel defined by platelet inhibition rate <20% measured by
             Verify Now before carotid stenting

          -  Patients with informed consent

        Exclusion Criteria:

          -  Antiplatelet therapy other than aspirin, clopidogrel, or ticlopidine

          -  Unable to perform MRI scans

          -  Patients with hematologic abnormalities including neutrophil <1500/ul, platelet
             <100,000/uL, or AST/ALT >120 U/L

          -  Unsuitable for participation
Clinical trial NCT02134210 (phase 3, status: completed)
Conditions: plaque psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: etanercept, chs-0214
SMILES: [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female adults

          -  PsO diagnosis for 6 months

          -  Active disease: PASI greater than or equal to 12, Physician's Static Global Assessment
             (PSGA) score greater than or equal to 3 (based on a scale or 0-5),

          -  Body Surface Area (BSA) involved with PsO greater than or equal to 10%

          -  Dermatology Life Quality Index (DQLI) greater than or equal to 10

          -  Previously received phototherapy or systemic non-biologic therapy for PsO

        Exclusion Criteria:

          -  Forms of Psoriasis other than PsO

          -  Drug induced Psoriasis

          -  Positive QuantiFERON-tuberculosis (TB) Gold Test

          -  Presence of significant comorbid conditions

          -  Chemistry and hematology values outside protocol specified range

          -  Major systemic infections
Clinical trial NCT02135029 (phase 3, status: completed)
Conditions: hyperlipidemia
ICD codes: E78.2, E78.49, E78.5
Drugs: bococizumab (pf-04950615;rn316), atorvastatin
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Hyperlipidemia

          -  Statin Intolerant

          -  Fasting LDL-C > = 70 mg/dL Fasting TG < = 400 mg/dL

        Exclusion Criteria:

          -  Pregnant or breastfeeding females

          -  Cardiovascular or cerebrovascular event or procedure within 90 days

          -  Severe or life-threatening adverse events with past use of statins

          -  Poorly controlled hypertension
Clinical trial NCT02135354 (phase 3, status: terminated)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: azithromycin, placebo
SMILES: [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    slow recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Established diagnosis of COPD by medical doctor (based on clinical history OR
             pulmonary function test)

          -  Smoking history of at least 10 pack-years (10 pack-years are defined as 20 cigarettes
             a day for 10 years, or 10 cigarettes a day for 20 years, etc.)

          -  Current hospitalization for potential infectious AECOPD treated with standard therapy

          -  History of at least one exacerbation during the last year (prior to the current
             hospital admission) for which systemic steroids and/or antibiotics were taken

          -  ECG at admission

        Exclusion Criteria:

          -  Mechanical or non-invasive ventilation at moment of randomization (D1)

          -  Long QT interval on ECG (QTc > 450msec for males or > 470msec for females)

          -  History of life-threatening arrhythmias

          -  Myocardial infarction (NSTEMI or STEMI) less than 6 weeks before start of study drug

          -  Unstable angina pectoris or acute myocardial infarction (NSTEMI or STEMI) at admission

          -  Drugs with high risk for long QT interval and torsade de pointes (amiodarone,
             flecainide, procainamide, sotalol, droperidol, haldol, citalopram, other macrolides)

          -  Documented uncorrected severe hypokalemia (K+ < 3.0 mmol/L) or hypomagnesemia (Mg2+ <
             0.5 mmol/L)

          -  Chronic systemic steroids (> 4 mg methylprednisolone /day for ≥ 2 months)

          -  Actual use of macrolides for at least 2 weeks

          -  Allergy to macrolides

          -  Active cancer treatment

          -  Life expectancy < 3 months

          -  Pregnant or breast-feeding subjects. Woman of childbearing potential must have a
             pregnancy test performed and a negative result must be documented before start of
             treatment
Clinical trial NCT02136134 (phase 3, status: active, not recruiting)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: daratumumab, velcade (bortezomib), dexamethasone
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Must have had documented multiple myeloma

          -  Must have received at least 1 prior line of therapy for multiple myeloma

          -  Must have had documented evidence of progressive disease as defined based on
             Investigator's determination of response of International Myeloma Working Group (IMWG)
             criteria on or after their last regimen

          -  Must have an Eastern Cooperative Oncology Group Performance Status score of 0, 1, or 2

          -  Must have achieved a response (partial response [PR] or better based on investigator's
             determination of response by the IMWG criteria) to at least 1 prior regimen in the
             past

        Exclusion Criteria:

          -  Has received daratumumab or other anti-CD38 therapies previously

          -  Is refractory to VELCADE or another PI, like ixazomib and carfilzomib (had progression
             of disease while receiving VELCADE therapy or within 60 days of ending VELCADE therapy
             or another PI therapy, like ixazomib and carfilzomib

          -  Is intolerant to VELCADE (ie, discontinued due to any adverse event while on VELCADE
             treatment)

          -  Has received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of
             the treatment, whichever is longer, before the date of randomization. The only
             exception is emergency use of a short course of corticosteroids (equivalent of
             dexamethasone 40 milligram per day [mg/day] for a maximum of 4 days) before treatment.
             A list of anti-myeloma treatments with the corresponding pharmacokinetic half-lives is
             provided in the Site Investigational Product Procedures Manual (IPPM).

          -  Has a history of malignancy (other than multiple myeloma) within 3 years before the
             date of randomization

          -  Has any concurrent medical condition or disease (eg, active systemic infection) that
             is likely to interfere with study procedures
Clinical trial NCT02136914 (phase 3, status: completed)
Conditions: dyskinesia, levodopa induced dyskinesia (lid), parkinson's disease
ICD codes: K22.4, G24.01, K22.4, G24.01, G20
Drugs: ads-5102
SMILES: NC12CC3CC(CC(C3)C1)C2
Eligibility criteria:

        Inclusion Criteria:

          -  Signed a current IRB/REB/IEC-approved informed consent form

          -  Parkinson's disease, per UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical
             Diagnostic Criteria

          -  On a stable regimen of antiparkinson's medications for at least 30 days prior to
             screening, including a levodopa preparation administered not less than three times
             daily, and willing to continue the same doses and regimens during study participation

          -  Following diary training, the subject is willing and able to understand and complete
             the 24-hour PD home diary (caregiver/study partner assistance allowed)

          -  Any other current and allowed prescription/non-prescription medications and/or
             nutritional supplements taken regularly must have been at a stable dose and regimen
             for at least 30 days prior to screening, and subject must be willing to continue the
             same doses and regimens during study participation (this criterion does not apply to
             medications that are being taken pre-study only on an as-needed basis)

        Exclusion Criteria:

          -  History of neurosurgical intervention related to Parkinson's disease (e.g. deep brain
             stimulation)

          -  History of seizures within 2 years prior to screening

          -  History of stroke or transient ischemic attack (TIA) within 2 years prior to screening

          -  History of cancer within 5 years prior to screening, with the following exceptions:
             adequately treated non-melanomatous skin cancers, localized bladder cancer,
             non-metastatic prostate cancer or in situ cervical cancer

          -  Presence of cognitive impairment, as evidenced by a Mini-Mental Status Examination
             (MMSE) score of less than 24 during screening

          -  If female, is pregnant or lactating

          -  If a sexually active female, is not surgically sterile or at least 2 years
             post-menopausal, or does not agree to utilize an effective method of contraception
             from screening through at least 4 weeks after the completion of study treatment.

          -  Treatment with an investigational drug or device within 30 days prior to screening

          -  Treatment with an investigational biologic within 6 months prior to screening

          -  Current participation in another clinical trial